Team leader :

Sylviane PIED


Sylviane Pied, PhD in Immunology in 1991, Research Director (DR) at CNRS, Basic and Clinical Immunology of Parasitic Diseases (BCIP) Team leader, partner of the LabEx PARAFRAP. She is also the coordinator of the Laboratoire International Associé Systems Immunology and genetic of Infectious Diseases (LIA SIGID). She has done her PhD on Malaria immunology with Pr D. Mazier at CHU Pitié Salpêtriere and her Post Doc with Pr V. Chauhan at ICGEB, India. She has been group leader at the Infectious Immunophysiopathology unit, Department of Immunology at Institut Pasteur Paris from 2001-2008.  Her main research interest in the study of the complex nature of immune responses contributing to protection or pathology in parasite infection.  SP is strongly involved in teaching activities and Master training mostly in Immunoparasitology. SP has hold several grants (EU, WHO, CEFIPRA, PAL+, ARCIR, PIME). She has organized several workshop, symposium and international courses in Immunology of parasitic diseases.

Our main research activity is focused on immunopathophysiology of protozoan parasite infection with a particular focus on malaria.  Malaria is a parasitic disease caused by Plasmodium (P.) transmitted by the bite of the infected Anopheles mosquito during its blood meal. Malaria affects about 250 million individuals and has multifaceted phenotypes varying from asymptomatic to severe disease. P. falciparum, one of the five species infecting humans leads to nearly 500,000 deaths per year.  Development of severe disease could be the result of a balance between pathological versus protective immune responses influenced by genetic and environmental factors. The project aims at evaluating the inappropriateness of the immune responses leading to severe disease during the course of infection in i) in inbred mouse strains infected with P. yoelii (acute non severe malaria, protective responses) and P. berghei ANKA (cerebral malaria, pathological responses; 2) Clinical, in P. falciparum infected patients manifesting different malaria sub-phenotypes ranging from asymptomatic to pernicious infection including appropriate controls from Gabon and Ivory Coast (children) and India (adults). Our ultimate goal is to identify disease phenotype biomarkers and/or target for new preventive immunotherapeutic strategies against severe malaria and death. The group has setted up an insectary for the developmental cycle of Plasmodium in the mosquito allowing to induce infection by bites of infected mosquito to mimic at best the natural transmission of malaria.


To top